Industry in brief | Acino, Dermapharm, Venture Life

Industry in brief | Acino, Dermapharm, Venture Life

30 March 2022 - Deborah Wilkes

  • Acino steps up presence in Saudi Arabia
  • Dermapharm reports sales up by 19%
  • Venture Life postpones financial results announcement

Acino steps up presence in Saudi Arabia

Acino has stepped up its presence in Saudi Arabia by establishing a legal entity and office in Jeddah.

The Switzerland-based pharmaceutical company, which set up a scientific office in Saudi Arabia in 2017, said the expansion followed “significant demand for its products and services”.

Acino’s plans include “exploring opportunities to collaborate with local manufacturers and produce select medications in the country”.

The move is part of Acino’s growth strategy in the Middle East and Africa region.

Acino is owned by ADQ, a holding company based in the United Arab Emirates (UAE) (click here to read the News story).

The Swiss company focuses on the Middle East, Africa, Latin America, Russia, Ukraine and the Commonwealth of Independent States (CIS). It has a presence in more than 90 countries.

Acino has made a number of acquisitions in recent years including a portfolio of OTC and prescription pharmaceuticals from Japan’s Takeda in 2019 in a deal worth more than USD200 million (click here to read the News story).

Dermapharm reports sales up by 19%

Dermapharm reported sales up by 19% to EUR943 million (USD1.05 billion) in 2021.

The German pharmaceutical company said growth had been boosted by the “continued high demand for products to strengthen the immune system, above all the vitamin D preparations of the Dekristol and Dekristolvit families”.

Sales had also been lifted by the acquisition in March 2020 of the Allergopharma allergy business from Germany’s Merck KGaA, said the company, as well as production of BioNTech’s vaccine for COVID-19.

The company’s Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) were up by 91% to EUR354 million in 2021, giving an EBITDA margin of 37.6%.

EBITDA adjusted for one-off costs was up by 75% to EUR351 million. The adjusted EBITDA margin was 37.2%.

Commenting on the prospects for 2022, Dermapharm said it expected sales to increase by between 10% and 13%, despite geopolitical and global economic developments and the ongoing COVID-19-pandemic.

Venture Life postpones financial results announcement

Self-care group Venture Life has postponed the release of its 2021 financial results until early April 2022, citing “resource issues”.

According to the UK-based company’s guidance released on 31 January 2022, sales reached GBP32.6 million, representing a rise of 8% compared to the same period a year earlier.

Sales in the first half of the year were GBP13.9 million, while sales in the second half were GBP18.7 million.

Click tags below for more information on topics:

Acino Dermapharm Venture Life

Back to Industry News

Share this page: